BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taylor RM, Jeong IH, May MD, Bergman EM, Capaldi VF, Moore NL, Matson LM, Lowery-gionta EG. Fear expression is reduced after acute and repeated nociceptin/orphanin FQ (NOP) receptor antagonism in rats: therapeutic implications for traumatic stress exposure. Psychopharmacology 2020;237:2943-58. [DOI: 10.1007/s00213-020-05582-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Gavioli EC, Holanda VAD, Calo G, Ruzza C. Nociceptin/orphanin FQ receptor system blockade as an innovative strategy for increasing resilience to stress. Peptides 2021;141:170548. [PMID: 33862163 DOI: 10.1016/j.peptides.2021.170548] [Reference Citation Analysis]
2 Al Yacoub ON, Awwad HO, Zhang Y, Standifer KM. Therapeutic potential of nociceptin/orphanin FQ peptide (NOP) receptor modulators for treatment of traumatic brain injury, traumatic stress, and their co-morbidities. Pharmacol Ther 2021;:107982. [PMID: 34480968 DOI: 10.1016/j.pharmthera.2021.107982] [Reference Citation Analysis]
3 Toll L, Cippitelli A, Ozawa A. The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies. CNS Drugs 2021;35:591-607. [PMID: 34057709 DOI: 10.1007/s40263-021-00821-0] [Reference Citation Analysis]
4 Velasco B, Mohamed E, Sato-Bigbee C. Endogenous and exogenous opioid effects on oligodendrocyte biology and developmental brain myelination. Neurotoxicol Teratol 2021;86:107002. [PMID: 34126203 DOI: 10.1016/j.ntt.2021.107002] [Reference Citation Analysis]